OKUR

OnKure Therapeutics, Inc. Class A Common Stock

2.67

USD

OKUR Earnings Reports

Positive Surprise Ratio

OKUR beat 11 of 19 last estimates.

58%

Next Report

Date of Next Report

Mar 09, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$1.17

Implied change from Q3 25 (Revenue/ EPS)

+7.34%

Implied change from Q4 24 (Revenue/ EPS)

-14.60%

OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On Nov 06, 2025, OKUR reported earnings of -1.09 USD per share (EPS) for Q3 25, beating the estimate of -1.22 USD, resulting in a 10.80% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.96% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of -1.17 USD, with revenue projected to reach -- USD, implying an increase of 7.34% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$1.09, beating estimates by 10.8%, and revenue of $0.00, 0% as expectations.

How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q3 2025 earnings?

The stock price moved down -6.96%, changed from $3.16 before the earnings release to $2.94 the day after.

When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Mar 09, 2026.

What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?

Based on 7 analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.17 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.